Patents Assigned to Abbott GmbH & Co. KG
  • Publication number: 20130149313
    Abstract: The present application relates to isolated proteins, particularly monoclonal antibodies, in particular CDR-grafted, humanized antibodies which bind to RAGE protein. Specifically, these antibodies have the ability to inhibit the binding of RAGE to its various ligands. The antibodies or portions thereof of described in the present application are useful for treating a disease or disorder characterized by or induced by pathophysiological ligands of RAGE, for example missfolded proteins like amyloid ? and advanced glycation-end-products.
    Type: Application
    Filed: November 27, 2012
    Publication date: June 13, 2013
    Applicants: ABBOTT LABORATORIES, ABBOTT GMBH & CO. KG
    Inventors: ABBOTT GMBH & CO. KG, ABBOTT LABORATORIES
  • Patent number: 8455648
    Abstract: The present invention relates to novel heterocyclic compounds which are useful for inhibiting glycogen synthase kinase 3 (GSK-3), methods of making the compounds, compositions containing the compounds, and methods of treatment using the compounds.
    Type: Grant
    Filed: April 24, 2009
    Date of Patent: June 4, 2013
    Assignee: Abbott GmbH & Co. KG
    Inventors: Sean Colm Turner, Margaretha Henrica Maria Bakker, Wilfried Hornberger
  • Publication number: 20130122519
    Abstract: The present invention relates to the identification and use of diagnostic markers for ischemic stroke of the lacunar subtype. The invention relates to devices and kits for performing these methods.
    Type: Application
    Filed: July 28, 2011
    Publication date: May 16, 2013
    Applicants: Institut de recerca Hoepital Universitari Vall D'Heerbron, Fundacio Privada, ABBOTT GMBH & CO. KG
    Inventors: Ingo Curdt, Stuart Blincko, Jens Dhein, Viswanath Devanarayan, Joan Montaner Villalonga
  • Publication number: 20130118238
    Abstract: A liquid mixture, comprising a) at least one compound selected from polyols, polyol ethers wherein at least one hydroxyl group is unetherified, or polyalkylene ethers wherein at least one terminal hydroxyl group is unetherified, b) 1,3-bis(caprolactam-1-yl) butane, and c) diacetoxybutane mimics the solubility properties of a graft copolymer comprising a poly(alkylene glycol) backbone and a vinyl acetate/N-vinylcaprolactam copolymer grafted onto the backbone. In a method for evaluating the compatibility of a biologically active substance with the graft copolymer i) the biologically active sub-stance is brought into contact with the liquid mixture, and ii) the phase behavior of the test system and/or the solubility of the biologically active substance in the mixture is determined.
    Type: Application
    Filed: February 15, 2011
    Publication date: May 16, 2013
    Applicant: Abbott GmbH & Co. KG
    Inventors: Jörg Breitenbach, Bernd Liepold, Jürgen Weis
  • Patent number: 8440694
    Abstract: The present invention relates to novel quinoline compounds of the formula (I) and to the salts thereof. The compounds possess valuable therapeutic properties and are particularly suitable, for treating diseases that respond to modulation of the serotonin 5-HT6 receptor. In formula (I) R is a moiety of the formula (R) wherein * indicates the binding site to the quinolinyl radical and wherein A, B, X?, Y, Q, R1, R2, R3, R4, R5, m, n, p, q, Ra, Rb, X and Ar are as defined in claim 1.
    Type: Grant
    Filed: September 13, 2012
    Date of Patent: May 14, 2013
    Assignee: Abbott GmbH & Co. KG
    Inventors: Sean Colm Turner, Wilfried Braje, Andreas Haupt, Udo Lange, Karla Drescher, Karsten Wicke, Liliane Unger, Mario Mezler, Matthias Mayrer, Andrea Hager-Wernet
  • Patent number: 8440626
    Abstract: The present invention provides antineoplastic peptides of formula I, I R1R2N-CHX-CO-A-B-D-E-(G)S-K wherein R1, R2, X, A, B, D, E, G, K and s have the meanings stated in the description. The compounds have antineoplastic activity.
    Type: Grant
    Filed: August 26, 2010
    Date of Patent: May 14, 2013
    Assignee: Abbott GmbH & Co. KG
    Inventors: Wilhelm Amberg, Teresa Barlozzari, Harald Bernard, Ernst Buschmann, Andreas Haupt, Hans-Guenther Hege, Bernd Janssen, Andreas Kling, Helmut Lietz, Kurt Ritter, Martina Ullrich, Jurgen Weymann, Thomas Zierke
  • Publication number: 20130116241
    Abstract: The present invention relates to novel compounds of the formula I which are inhibitors of phosphodiesterase type 10A and to their use for the manufacture of a medicament and which thus are suitable for treating or controlling of medical disorders selected from neurological disorders and psychiatric disorders, for ameliorating the symptoms associated with such disorders and for reducing the risk of such disorders.
    Type: Application
    Filed: October 25, 2012
    Publication date: May 9, 2013
    Applicants: AbbVie Inc., Abbott GmbH & Co. KG
    Inventors: Abbott GmbH & Co. KG, AbbVie Inc.
  • Publication number: 20130116233
    Abstract: The present invention relates to novel compounds of the formula I which are inhibitors of phosphodiesterase type 10A and to their use for the manufacture of a medicament and which thus are suitable for treating or controlling of medical disorders selected from neurological disorders and psychiatric disorders, for ameliorating the symptoms associated with such disorders and for reducing the risk of such disorders.
    Type: Application
    Filed: October 29, 2012
    Publication date: May 9, 2013
    Applicants: AbbVie Inc., Abbott GmbH & Co. KG
    Inventors: Abbott GmbH & Co. KG, AbbVie Inc.
  • Publication number: 20130116229
    Abstract: The present invention relates to compounds which are inhibitors of phosphodiesterase type 10A and to their use for the manufacture of a medicament and which thus are suitable for treating or controlling of medical disorders selected from neurological disorders and psychiatric disorders, for ameliorating the symptoms associated with such disorders and for reducing the risk of such disorders.
    Type: Application
    Filed: November 8, 2012
    Publication date: May 9, 2013
    Applicants: AbbVie Inc., Abbott GmbH & Co. KG
    Inventors: Abbott GmbH & Co.KG, AbbVie Inc.
  • Patent number: 8436034
    Abstract: The present invention relates to novel carboxamide compounds and their use for the manufacture of a medicament. The carboxamide compounds are inhibitors of calpain (calcium dependant cysteine proteases). The invention therefore also relates to the use of these carboxamide compounds for treating a disorder associated with an elevated calpain activity. The carboxamide compounds are compounds of the general formula I in which R1, R2, R3a, R3b, W, Y and X have the meanings mentioned in the claims and the description, the tautomers thereof and the pharmaceutically suitable salts thereof. In particular, the compounds have the general formula I-A.a? and I-A.a? in which m, E, R1, R3a, R3b, R2, Ry, Rw and Rw6* have the meanings mentioned in the claims, n is 0, 1 or 2, the tautomers thereof and the pharmaceutically suitable salts thereof.
    Type: Grant
    Filed: December 28, 2007
    Date of Patent: May 7, 2013
    Assignee: Abbott GmbH & Co. KG
    Inventors: Andreas Kling, Wilfried Hornberger, Helmut Mack, Achim Moeller, Volker Nimmrich, Dietmar Seeman, Wilfried Lubisch
  • Patent number: 8431567
    Abstract: The present invention relates to novel oxindole derivatives of general formula (I), in which the substituents R1, R2, A, B and Y are as defined in claim 1, medicinal products containing them and use thereof for the prophylaxis and/or treatment of vasopressin-dependent and/or oxytocin-dependent diseases.
    Type: Grant
    Filed: August 24, 2007
    Date of Patent: April 30, 2013
    Assignee: Abbott GmbH & Co. KG
    Inventors: Herve Geneste, Thorsten Oost, Astrid Netz, Charles W. Hutchins, Wolfgang Wernet, Wilfred Lubisch, Liliane Unger, Wilfried Hornberger
  • Patent number: 8431604
    Abstract: The present invention relates to guanidine compounds of the general formula I corresponding enantiomeric, diastereomeric and/or tautomeric forms thereof as well as pharmaceutically acceptable salts thereof. The present compound further relates to the use of guanidine compounds as binding partners for 5-HT5 receptors for the treatment of diseases which are modulated by a 5-HT5 receptor activity, in particular for the treatment of neurodegenerative and neuropsychiatric disorders as well as the associated signs, symptoms and dysfunctions.
    Type: Grant
    Filed: February 15, 2005
    Date of Patent: April 30, 2013
    Assignee: Abbott GmbH & Co. KG
    Inventors: Astrid Netz, Wilhelm Amberg, Udo Lange, Michael Ochse, Charles W. Hutchins, Francisco-Xavier Garcia-Ladona, Wolfgang Wernet, Andreas Kling
  • Patent number: 8420670
    Abstract: The present invention relates to 4-benzylaminoquinolines of the formula (I) or physiologically tolerated salts thereof. The invention relates to pharmaceutical compositions comprising such quinolines, and the use of such quinolines for therapeutic purposes. The quinolines are GIyTI inhibitors.
    Type: Grant
    Filed: August 22, 2008
    Date of Patent: April 16, 2013
    Assignees: Abbott Laboratories, Abbott GmbH & Co. KG
    Inventors: Wilhelm Amberg, Michael Ochse, Wilfried Braje, Berthold Behl, Wilfried Hornberger, Mario Mezler, Charles W. Hutchins
  • Patent number: 8383641
    Abstract: The present invention relates to aryloxyethylamine compounds of the formula I and the physiologically tolerated acid addition salts thereof. The variables have the meanings given in the claims and the description. The invention also relates to the use of a compound of the formula I or a pharmaceutically acceptable salt thereof for preparing a pharmaceutical composition for the treatment of a medical disorder susceptible to treatment with a dopamine D3 receptor ligand.
    Type: Grant
    Filed: April 13, 2007
    Date of Patent: February 26, 2013
    Assignee: Abbott GmbH & Co. KG
    Inventors: Roland Grandel, Wilfried Martin Braje, Andreas Haupt, Sean Colm Turner, Udo Lange, Karla Drescher, Liliane Unger
  • Publication number: 20130035323
    Abstract: The present invention relates to aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives of the formula (I) or a physiologically tolerated salt thereof. The invention relates to pharmaceutical compositions comprising such aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, and the use of such aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives for therapeutic purposes. The aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives are GlyT1 inhibitors.
    Type: Application
    Filed: August 3, 2012
    Publication date: February 7, 2013
    Applicant: Abbott GmbH & Co. KG
    Inventors: Wilhelm AMBERG, Udo LANGE, Frauke POHLKI
  • Publication number: 20130029966
    Abstract: The invention relates to novel oxindole derivatives of general formula (I), wherein the substituents R1, R2, A, B, and Y are defined as in Claim 1. The invention further relates to medicaments containing said derivatives, and use thereof for the prevention and/or treatment of vasopressin-dependent diseases.
    Type: Application
    Filed: September 23, 2011
    Publication date: January 31, 2013
    Applicant: Abbott GmbH & Co. KG
    Inventors: Thorsten Oost, Wilfried Lubisch, Wilfried Hornberger, Liliane Unger, Herve Geneste, Astrid Netz
  • Patent number: 8362010
    Abstract: The present invention relates to novel benzenesulfonanilide compounds of the formulae I and I? and physiologically tolerated acid addition salts and the N-oxides thereof. The compounds possess valuable therapeutic properties and are particularly suitable, for treating diseases that respond to modulation of the serotonin 5-HT6 receptor. wherein R1 is hydrogen or methyl; R2 is hydrogen or methyl and is positioned vicinal to the radical R1; R3 hydrogen, C1-C3 alkyl, halogen, C1-C3 alkoxy, fluorinated C1-C3 alkyl or fluorinated C1-C3 alkoxy; R4 is hydrogen, C1-C4 alkyl, C3-C4 cycloalkyl, C3-C4 cycloalkylmethyl or fluorinated C1-C4 alkyl; R5 is hydrogen, fluorine, chlorine, C1-C4 alkyl, fluorinated C1-C4 alkyl, C1-C4 alkoxy or fluorinated C1-C4 alkoxy; and R6 is hydrogen, fluorine or chlorine.
    Type: Grant
    Filed: April 29, 2010
    Date of Patent: January 29, 2013
    Assignees: Abbott GmbH & Co. KG, Abbott Laboratories
    Inventors: Andreas Haupt, Frauke Pohlki, Karla Drescher, Karsten Wicke, Liliane Unger, Ana-Lucia Relo, Anton Bespalov, Barbara Vogg, Gisela Backfisch, Juergen Delzer, Min Zhang
  • Publication number: 20130018047
    Abstract: The present invention relates to N-phenyl-(piperazinyl or homopiperazinyl)-benzenesulfonamide or benzenesulfonyl-phenyl-(piperazine or homopiperazine) compounds, pharmaceutical compositions containing them, and their use in therapy. The compounds possess valuable therapeutic properties and are particularly suitable for treating diseases that respond to modulation of the serotonin 5-HT6 receptor.
    Type: Application
    Filed: September 14, 2012
    Publication date: January 17, 2013
    Applicants: Abbott Laboratories, Abbott GmbH & Co. KG
    Inventors: Andreas Haupt, Frauke Pohlki, Karla Drescher, Karsten Wicke, Liliane Unger, Ana-Lucia Relo, Anton Bespalov, Barbara Vogg, Gisela Backfisch, Juergen Delzer, Min Zhang, Yanbin Lao
  • Patent number: 8349843
    Abstract: Carboxylic acid derivatives where R—R6, X, Y and Z have the meanings stated in the description, and the preparation thereof, are described. The novel compounds are suitable for controlling diseases.
    Type: Grant
    Filed: October 6, 2011
    Date of Patent: January 8, 2013
    Assignee: Abbott GmbH & Co. KG
    Inventors: Hartmut Riechers, Dagmar Klinge, Wilhelm Amberg, Andreas Kling, Stefan Muller, Ernst Baumann, Joachim Rheinheimer, Uwe Vogelbacher, Wolfgang Wernet, Andrea Hager-Wernet, legal representative, Liliane Unger, Manfred Raschack
  • Patent number: 8350055
    Abstract: The present invention relates to novel 1,3-dihydroindol-2-one (oxindole) derivatives of the formula (I) in which A, R3, R4, R5, R6, and R7 are defined according to claim 1, and to medicaments containing them for the treatment of diseases. In particular, the novel oxindole derivatives can be used for the control and/or prophylaxis of various vasopressin-dependent or oxytocin-dependent diseases.
    Type: Grant
    Filed: July 20, 2010
    Date of Patent: January 8, 2013
    Assignee: Abbott GmbH & Co. KG
    Inventors: Thorsten Oost, Wilfried Hornberger, Herve Geneste, Daryl Richard Sauer, Wolfgang Wernet, Andrea Hager-Wernet, legal representative, Liliane Unger, Wilfried Lubisch